Table 4 Predictors of LUNDEX-corrected HAQ response. Odds ratios (95% confidence intervals)

Male sex

1.07 (0.73–1.58)

*

1.32 (0.91–1.90)

**

≥ 2 bDMARDs

Reference (1.0)

Reference (1.0)

Reference (1.0)

Reference (1.0)

Bionaïve

2.25 (1.50–3.38)

2.31 (1.49–3.60)

2.05 (1.37–3.07)

2.05 (1.37–3.07)

1 bDMARD

1.02 (0.71–1.47)

*

0.70 (0.48–1.04)

**

DAS28-CRP (per SD) at baseline

1.48 (1.26–1.74)

*

1.38 (1.17–1.62)

**

DAS28 (per unit) at baseline

1.40 (1.23–1.60)

*

1.27 (1.12–1.45)

**

VAS pain (per SD) at baseline

1.45 (1.23–1.70)

*

1.24 (1.05–1.47)

**

Methotrexate at baseline

1.50 (1.10–2.05)

*

1.39 (1.01–1.90)

**

HAQ score (per SD) at baseline

1.52 (1.29–1.78)

1.73 (1.46–2.05)

1.24 (1.06–1.45)

**

Disease duration (per SD) at baseline

0.77 (0.65–0.91)

0.74 (0.61–0.89)

0.78 (0.65–0.92)

**

Age (per SD) at baseline

0.93 (0.80–1.08)

*

1.00 (0.86–1.17)

**

Glucocorticoids at baseline

0.75 (0.55–1.01)

*

0.83 (0.61–1.13)

**

csDMARDs at baseline

1.30 (0.94–1.81)

*

1.17 (0.84–1.62)

**

s.c. abatacept administration

Reference (1.0)

*

Reference (1.0)

*

i.v. abatacept administration

0.98 (0.73–1.33)

*

0.97 (0.71–1.32)

**